CNS Disease   

Questions discussed in this category


Would you offer consolidative brain SRS, SRS + consolidative RT to the primary (e.g. lung), consolidative RT to the primary alone?

Which regimen is preferred in second line for these patients? What is the efficacy of TDXd vs tucatinib in CNS metastases?    

Would the rate of growth, number of nodes involved, size of nodes, ENE etc. affect your decision?   What volume and dose would you recommend?

Aside from symptomatic disease, is there a certain growth cutoff or other criteria that would be a trigger for treatment?


Papers discussed in this category


Multiple sclerosis (Houndmills, Basingstoke, England), 2014-01

Ann. Neurol., 2018 Feb 15

N. Engl. J. Med., 2019 Dec 11

J Clin Oncol, 2020 May 29

N Engl J Med,

N Engl J Med, 2019 Dec 11

Int. J. Radiat. Oncol. Biol. Phys., 2011 Jun 15

Cancer, 2004-12-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-09-20